EGFR and non-small cell lung carcinoma: Although immune checkpoint inhibitors, such as anti‐programmed death ligand 1 (PD‐L1) or PD‐1 agents, have yielded improved survival for NSCLC patients lacking sensitizing driver mutations [3, 4], their use as initial therapy for patients with sensitizing EGFR mutations is not recommended due to lack of effectiveness [5, 6, 7].